

आई. सी. एम. आर. – राष्ट्रीय कॉलरा और आंत्र रोग संस्थान ICMR - NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES

स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य और परिवार कल्याण मंत्रालय, भारत सरकार Department of Health Research, Ministry of Health and Family Welfare, Govt. of India

WHO COLLABORATING CENTRE FOR RESEARCH AND TRAINING ON DIARRHOEAL DISEASES

Ref. No.NICED/Stores/VRDL Proj./Printing/2022-23

Date: 21/02/2023

QUOTATION ENQUIRY

Sealed quotations are invited on behalf of Director, ICMR-NICED, Kolkata for Printing and supply of following forms as per the specifications. The quotations addressed to Director, ICMR-National Institute of Cholera & Enteric Diseases, P-33, C.I.T Road, Scheme – XM, Beliaghata, Kolkata – 700010 may be sent so as to reach this office on or before 28/02/2023. The quotation will be opened on same day by 3.30 p.m.

Sl.	Particulars of the item	Qty.	Quoted Rate
No.			(INR)
01.	Case Record Form (CRF) (Both side print in 80 GSM paper)	5000 copy	
02.	Test Record Form (TRF) (Both side print in 80 GSM paper)	5000 copy	
03.	RNA Extraction Sheet (Both side print in 80 GSM paper)	2000 сору	
04.	SARI Form & Treatment Form (2 sheet both side print in 80 GSM paper)	10,000 copy	
05.	ILI Form (Both side print in 80 GSM paper)	3,000 copy	
06.	Consent Form (English) (Both side print in 80 GSM paper)	1,000 copy	
07.	Consent Form (Bengali) (Both side print in 80 GSM paper)	1,000 copy	
08.	Patient identification slip (PID) (Both side print in 80 GSM paper)	2,000 copy	
	S	ub-total :	
	G	ST@	
	Total amount in	cluding GST:	

Terms and conditions:

- 1) This is an enquiry & must not be treated as an order
- 2) The Director, ICMR-NICED reserves the right to accept or reject the quotations without assigning any reasons thereof.
- 3) The last date may be extended subject to requirement.
- 4) Any decision taken by the Director, ICMR-NICED at any point of time in connection with this process shall be final and conclusive and no claim or dispute from any query in this regard shall be entertained.
- 5) No advance payment will be made. The payment will be made on rendering the services availed and satisfactory report of the end user(s).
- 6) No extra payment on account of transportation, handling, loading, unloading, labour charges etc. will be made. However GST as per rules will be permissible.
- 7) While submitting the quotations the rate against each work and net amount to be paid, GST etc. should be specified separately.
- 8) ICMR-NICED, Kolkata does not bind itself to accept the lowest quote & reserves the right to accept the same in part or full.
- 9) Please ensure that the supply is as per the specification

Store-in-Charge
National Institute of Cholera
and Enterio Diseases
P-33, C.I.T. Road, Scheme-XM



ICMR - NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES

DHR-ICMR Virus Research and Diagnostic Laboratory Network (Ver 3.0)

CASE RECORD FORM

Format No.: NICED/VRDL/FM-002/Ver. 1.0

A. Iden	tification Section						2017		COLORA DI SERVICIO	2000年
Lab cod	de 0 3 4	Year		P	atient ID (issued	by VI	RDL)	an a (200) .		
1.Samp	le Origin		16 1	□ /aa	to page 2)		ate (DD/N	IIVI/YY):		l
	c / disease cluster (Referred				to page 2) Outbrea to page 2) Medical	k : Invest college/R	igation date Ref. Hosp. : Patie	nt Visit date (OP)/ Admission date (II	P)
	c / disease cluster (investiga				to page 2) Incarea					
Medical	College/ Referral Hospital									
B Patie	ent Information									
	ent name			mes					II ATILIE	
- COUNTY	D/o W/o		- 80×A.		4. Age in		For Infan	ts month	s days	
	Male 🗌 Female 🗌		THE POPE TO A		6. Contact Nu	mber	:			
				_			1011		mi v l služidan	
7. Patie							-	- l. d. /Tala	all .	
Address	S.		a magni e sumuk 8650	<u>. J. J.</u>				aluk/Teh		
	District :		Pin Code :		State :	m 9	R	ural/Urb	an/NK:	
8. Patie		11 11 111	b. Out-patient]	9. Hospital Of	/IP n	umber :		yan makhirin da	
The second second second second	me of clinician:	ed Auto	s Instrumental Phile School		11. Clinician's	Conta	act numbe	r:	and travel	
	erral Hospital name:								tion was at	
	cal Details (Tick all tha	at apr	oly)			Water A				
	e of onset of illness (DI			41.5	14. Duration o	f illne	ss (in days):	100 (100)	
13. Date	Syndromes	7	Ed fragator of the	1	Associated	Symp	otoms	idls	tit same	
	-,		1. Fever		2. Diarrhoea		3. Dysent	ery	High Made a con-	
15. Dia	rrhoea		4. Pain in abdomen	N/I	5. Vomiting		6. Others	(specify)	publicanus en e	
				_	2. Sore throat	П	3. Cough		4. Rhinorrhoe	a 🗆
		\Box	1. Fever						4, 11,,,,,,	
16. Res	piratory	ш	5. Breathlessness		6. Others (spec	ify)				
17. Fev	er of Unknown Origin		1. Fever		2. Any localizin	g sysn	nptoms 🗆			
	The state of the state of	11	1. Fever		2. Macular		3. Papule	. 🗆		
			4. Maculo-papular		5. Eschar		6. Pustul	e 🗆	1524500 15V.A.	
18. Ras	sh			_	8. Others (Spec	ify)			bear I lil	
			7. Bullae				3. Dark u	rine 🗆	4. Hepatome	aalv 🗆
	l'	\Box	1. Fever		2. Jaundice	711			FORTILE.	
19. Jau	indice	Ш	5. Nausea		6. Vomiting				n/discomfort	
	THOUSEN AND STREET	1 4	1. Fever		2. Irritability		3. Increa	sed Somi	nolence	
			4. New onset of Seizur	res 🗆	5. Neck rigidity	/ 🗆	6. Altere	d sensori	um	
20. End	cephalitis / Meningitis		7. Change in mental st				_			
					8. Others (Spe	cify)				
					2. Rigors		3. Heada	iche 🗆		
			1. Fever		5. Malaise		6. Arthro			
24 115	omorrhagic Foyer		4. Chills							
Z1. Had	emorrhagic Fever		7. Myalgia		8. Haemorrhag		and the second second	is ⊔		
			9. Retro-orbital pain		10. Others (Sp	ecify)			2	
22. Coi	njunctivitis		1. Fever		2. Redness		3. Dische	arge 🗆	4. Crusting	
23. Otl	her Syndrome		Specify							
24 Dro	ovisional diagnosis :				25. Investigat	ions R	equested	:	16	
24. Pro	Visional diagnosis .									
			OM Pay	378	atemiseum sadu	d not	dal radial		Land D. L.	
The second second	Epidemiological Deta	-						et hot	19.4 Sept. 65.2 No. 35.2	
26	6.Presence of similar of	ase ir	the house		Yes □ Λ	lo 🗆	nn nots si e	os brogles	i Sisti (to milital)	_
27	7.Presence of similar o	ase/s	in the village/locality		Yes □ Λ	lo 🗆				_
	3. History of travel in la				Yes □ Λ	lo 🗆			T. American Co.	
-	1911		1 3 2 4		If Yes, pla	ace vi	sited		V STATE OF THE STA	

Name of the person filling form: Signature of person filling form:



Date:

ICMR - NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES DHR-ICMR Virus Research and Diagnostic Laboratory Network (Ver 3.0)

Format No. : NICED/VRDL/FM-002/Ver. 1.0

To be filled only for Patients/samples form Outbreak*

To be filled only for Patients/samples form Seasons *(samples sent by PHC/CHC/Dist. Health authorities and investigated by VRDL for confirmation of Outbreak/disease clusters)	er)
*(camples sent by PHC/CHC/Dist, Health authorities and investigated by VRDL for confirmation of Outbreak assessment	,
(samples series) They end, and	

E. Patient Infor	mation (to be	filled by	VRDL)	D/= 11	l la	ひかい 単純		Visit State Name of				
1. Patient name	e			2. 5/0	D/o W	/0	7		1 4 6	ov - 14	lale 🗆	Female [1
3. Age in comp	leted	E	or Inj									· cr.iaic _	_
							Ctate	٠.	FIL	Ru	ral / Url	ban / NK :	
. I I D	istrict :	wă 📗	Ale -	Pin Co	form	nuthrea				1			
Contact details	of the official	referring	tne sa	amples	iomi	Julinea	K. INGII						
	mbor licerad his	VRDI)				7. Date	of samp	le collectio	n:	П	P01.5	entre po	_
		TRUL				9. Tota	Inumber	of patient	s form wh	om sa	mples a	re collected	1:
8. Date of Onse	t of symptoms:					10. Pat	ient Num	ber within	the outb	reak :	-		
11. Which of the	e following best	describe t	the cli	nical pr	resenta	ion? (Ti	k most a	ppropriate	option)		tod don	muo)	
a. Fever w	vith rash (suspe	cted meas	les/ru	bella)		b.	Fever w	ith rash, a	rtriraigia (1
		the second control of) 🗆	d.							a)
						f.	Fever w	ith neurolo	gical sym	ptoms	(suspect	ed JE)	
g. Fever v	vith haemorrha	gic manife	Statio	// IS	440	,,,				d born	e)	uLine	
I. Conjund	ctivitis	Title Heat	15 - Ju	-topo		J.							
k. Acute	flaccid paralysis	(c)		9300	1709				-4.				_
				III.		13. lnv	estigation	ns Request	ea:				
Date of received													
	nple/s received	/collected	by (N	lame):	langua di San								
		Li Ladie						- 101	Date:				
				T			11.						
		Date of	Testin	g	Samp	ole Type		Test	done			Result	-
	Viius						in Kin	N. 10.00			-		-
			11(1)	1514				-					-
3.													
4.		and A			The state of								
5.					+							al San Lu	
		1122	C 121 1	emir	-			1.6	-11 1				_
		-	-					coll w.Sc	Tag T				
					+								
		- t- T			-								
		 			+								
									11 11 11				_
													_
c. Fever with arthralgia (suspected Chikungunya)													
	ample sent to	higher lal	o for f	further	invest	igations	Ye	s No					
Patient Name 2. S/o Uy Viv													
Name of	the Technician	s perform	ing te	est :				Name	of the lab	in-cha	rge :		
Tarric of		•	_										
								Clanat	ure of lak	n in-ch	arge :		
Signatur	e of Technician	perform	ing te	est :				Signat	uic oi iai	J 111 OIT			
-												Page 2/2	2



Format No. - NICED/VRDL/FM-001/Ver. 1.0

ICMR - NATIONAL INSTITUTE OF CHOLERA & ENTERIC DISEASES

Regional Virus Reaseach and Diagnostic Laboratory (VRDL)

Contact: 033 2370 / 4478 / 0448; 2353 7469; Ext 121 / 190 Email: vrdln.niced@gmail.com Website: http://www.niced.org.in/niced/VRDL-ICMR-NICED.htm

ttp://www.niced.org.in/niced/VKDL-i	Site ID:	/ Lab ID:/_	
TEST REQUEST I	FORM		

	TEST REQUE	ST FORM	
Name of patient (in blo	ock letters):		
Age:	Sex:		
Address (in detail):			
District:		PIN code:	
Contact No :			
	/In nationt	Ward:	Bed No.:
Patient type: Out-Pa	tient /in-patient	******	
Patient registration (I	PD/OPD) no.:		
Imme of patient (in block letters): See: Sex: Seme of guardian: Iddress (in detail): Iddress (In detail):	ontact no.:		
Name of referring hos	spital :	Land Total	e mano te no i
Date of onset of illne	dress (in detail): strict: PIN code: ntact No.: tient type: Out-Patient /In-patient Ward: Bed No.: tient registration (IPD/OPD) no.: ame of referring clinician: Clinician's contact no.: ame of referring hospital: ate of onset of illness: elevant sings and sysnptoms: listory of past illness: xposure history: listory of travel in last 15 days: siochemical parameters: Haemoglobin Haematocrit (%) WBC count Neutrophil (%) Lymphocytes (%) Monocytes (%) Platelet Count Procalcitonin ESR CRP Procalcitonin Conjugated		
Melevanie singe and a	me of patient (in block letters): Sex: me of guardian: dress (in detail): dress (i		
History of past illnes	S:		
•			
*			
History of travel in la	ast 15 days:		
Riochemical parame	eters:	THE SHEET STREET AND INTEREST OF THE	
	Haematocrit (%)		0
	Lymphocytes (%)		
			t
Serum bilirubin	Unconjugated	or 101 argunts, Septicing	in a second of the second
	Serum AST		
	Albumin/globulin ra		
DT	APTT	INR	110 - 10 - 10 - 10 - 10 - 10 - 10 - 10
Serum Urea	Serum Creatinine		and a starting with the other

Others



Format No. - NICED/VRDL/FM-001/Ver. 1.0

ICMR - NATIONAL INSTITUTE OF CHOLERA & ENTERIC DISEASES Regional Virus Reaseach and Diagnostic Laboratory (VRDL)

Contact: 033 2370 / 4478 / 0448; 2353 7469; Ext 121 / 190 Email: vrdln.niced@gmail.com Website: http://www.niced.org.in/niced/VRDL-ICMR-NICED.htm

Serological investigations:	
	considered with injection in the con-
Chest X-ray findings:	
USG findings:	
CT scan/MRI findings:	and a distriction of the second
Immunization history:	
Whether known to be pregnant: Yes \Box / No \Box	Gestation period:
Co-morbidity (if any):	
	See and the second seco
Category which the patient belongs to (for suspect	ed Influenza):B(i) 🔲 / B(ii) 🔲 / C 🔲
Provisional diagnosis:	
Investigations requested:	
	grad Alight Tall Indian
Type of specimen:	
Date of specimen collection:	Time of specimen collection:
Name of person collection the specimen:	
Name of person filling the form:	
Email ID of concerned hospital/clinician:	
	Signaturo & Soal

Signature & Seal

- Specimen receiving counter: ICMR-NICED Virus Laboratory, GB4,1st Floor, ID&BG Hospital, Beliaghata.
- Specimen receiving time: Monday Saturday (10.30 am to 05.00 pm)
- The patient party will be communicated about the day of generation of report at the time of receiving specimen.
- Requests for investigations (other than influenza A H1N1) from private hospital/clinician should be forwared via IDSP / State Health Department.
- Diagnostic report of Influenza A H1N1 will be communicated only via email to the concerned hospital/clinician
 and state Health Department within 2 working days. No printed report will provided to the patient party.
- Refer to the website for detailed information regarding investigation performed at Regional VRDL, ICMR-NICED.

SAF Tick ($$) in the appropriate box	RI (IPI) CAS	E PROFORMA							
Admitted patient (IPD)					**********					
General Medicine			Pediatrics							
Respiratory Medicine			ICU							
Geriatric Medicine			Other							
Date of Onset of Symptoms		111	15 M - 7 M I	<u> </u>						
Date of Sample Collection										
Study ID:	mental and a second		ealth Facility:	ida, a chall dha ballar, an a chlèinea	Science and another second					
Patient Reg Number: Contact number:		ient Nai	Male Female	8-81 PE-8-8-8-97 18-8-91 P1/PE-8-91 8						
Age: Year Month Birth			Wate Female	in	T					
	hroat sy		Nasopharyngeal swab Ot	her						
Informant Self	-	aregive		•						
Complete address: Village/Town/	I	<u>-</u>	District:							
Rural			Urban							
The state of the s	ight (kg	g):	***************************************							
Pregnancy: Yes No			if Yes, Gestational age in mon	ths:						
For children under 5 year Mid arm c	ircumfe	erence (c	em):							
Exposure History	Yes	No	Exposure History		Yes I					
Similar illness in family/neighbor	5		Smoking (self)/ Smoker in	family						
Exposure to poultry/dead bird			Exposure to farm animals							
No. of family members sleeping in			H/o travel abroad in past 14	days						
same room			prior to onset		**					
Symptoms	Yes	No	Symptoms	Yes	No					
Fever/History of fever (< 7 days)			Chills							
Rigors			Cough							
Sputum Production			Haemoptysis							
Sore throat			Nasal Discharge/stuffiness							
Ear ache/ discharge			Headache							
Body-ache			Malaise/Fatigue							
Chest Pain			Abdominal pain							
Vomiting/nausea			Diarrhea							
Breathlessness/ difficulty breathing			Seizures		-					
			Seizures							
Other Symptoms:										
For Children Under 5 Years				_						
Decreased feeding			Lethargy/unconscious							
				1	1					
Vaccination History	Yes	No	Treatment History	Yes	No					
H/o influenza vaccination within			Antivirals (Tamiflu) in past	7						
last 1yr			2 weeks		1					

Annexure-II

COVID-19 Vaccination		
First Dose: Covaxin / Covishield / Sputnik V (Date)		r
Second Dose: Covaxin / Covishield / Sputnik V (Date)		

Clinical Signs	Ente	r Value	Clinical Signs	Enter	Value
Respiratory rate/minute:			Pulse rate/minute:		
O ₂ saturation (%):			Axillary temperature (°C):		
BP systolic: BP	diastolic:				
	Yes	No		Yes	No
Wheeze			Nasal flaring		
Stridor in calm patient			Crepitation		
Lower chest in-drawing			Grunting		
Apnea			Accessory muscles use for breathing		
Other					

Medical History	Yes	No	Not known	Medical History	Yes	No	Not known
Chronic lung disease (COPD/Bronchitis)				Asthma	ž.		
Tuberculosis				Heart Diseases			
Diabetes				Chronic liver disease			
Chronic renal disease				Chronic neurological disease			
Hematologic disorders e.g. Thalassemia				Malignancy /Cancer			
Immunocompromised state/ steroid therapy				HIV			
Chronic diarrhea in children under 5 years				H/o influenza vaccination within last 1 year			
Hypertension							
Other (specify):				•			1

Treatment	Yes	No	Treatment	Yes	No
Antibiotics			Antivirals (Tamiflu/ Zanamavir/ Peramivir) in past 2 weeks		
Oxygen			Steroid		
Mechanical ventilation (intubation)			Bronchodilators		
CPAP (Continuous positive airway pressure					
Other:	1				

Annexure-II

Investigations			
Hematocrit:			
Hb:			
WBC (leukocytes) count:			
Differential leukocytes count	1		
Lymphocytes (%):			
Monocytes (%)			
Neutrophil (%):			
Basophil (%):			
Eosinophil (%):			
Platelet (Thrombocytes) Count:			
ESR:			
Chest X-ray done	Yes	No	
Chest X-ray → Findings by	Consolidation	Infiltration	Diffuse ADDC
radiologist	Consolidation	inititration	Diffuse ARDS
Blood Culture → Findings if any			
Admitted in ICU Yes	No		
Date of ICU admission			
Sepsis Yes	No	-	
Physician clinical diagnosis:			
Final Outcome		i e	
Discharged alive	Date of discharge		2
Death/Died	Date of death		
Sign of			
Signature	-		
Name of interviewer	9		
Date			

Annexure-I

ILI (OPD) CASE PROFORMA

Name of CHC / PHC:

ate of Onset of Sympt		n n			Y Y DDD		
ate of Sample Collect		Mama	£ Haaltla	Facility:	7		
udy ID: atient Reg Number:		Patient 1		racility:			
ontact number:	ii	Gender:		Male	Female		
ge: Year		Date of			A/ A/ Y	Y Y	TY
	Nasal Swab		hroat sy	vab	Nasopharynge	al swab	
	Self		aregive				
omplete address:	Village/Town/C				District:		
	Rural			Url	ban		
eight (cm):	Weight (kg):						
	es No			stational age in	n months:		
or children under 5 ye	ar: Mid arm circumf	erence (cm):				
Exposu	re History	Yes	No	Expo	sure History	Ye	s N
	n family/neighbor				elf)/ Smoker in fami	ily	
Exposure to pou	ltry/dead bird				farm animals		
	embers sleeping in				broad in past 14 day	/S	
same room				prior to onse	et		
Symptoms		Yes	No	Symptom	ıs ·	Yes	No
	of fever (< 7 days)			Chills			
Rigors				Cough			
Sore throat				Haemopt	ysis		
Ear ache/ disc	harge			Nasal Di	scharge/stuffiness		
Body-ache				Headach	e		
Chest Pain				Malaise/	Fatigue		
Vomiting/naus	sea			Abdomin	al pain		
Breathlessness	s/ difficulty breathin	g		Diarrhea	=		
Seizures							
Other Sympto	ms:						
For Children	Under 5 Years	_					
Decreased fee	ding			Lethargy	/unconscious		

Annexure-I

Medical History	Yes	No	Not known	Medical History	Yes	No	Not known
Chronic lung disease (COPD/Bronchitis)				Asthma			
Tuberculosis				Heart Diseases			
Diabetes				Chronic liver disease			
Chronic renal disease				Chronic neurological disease			
Hematologic disorders e.g. Thalassemia				Malignancy /Cancer			
Chronic diarrhea in children under 5 year				Other (specify):		l,	
Hypertension							

Vaccination History	Yes	No	Treatment History	Yes	No
H/o influenza vaccination within last 1yr			Antivirals (Tamiflu) in past 2 weeks		
COVID-19 Vaccination			,		
First Dose: Covaxin / Covishield / Sputnik V (Date)					
Second Dose: Covaxin / Covishield / Sputnik V (Date)					
Signature			1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -		
Name of interviewer					

TREATMENT

Antibiotics:
Starting Date Weaning Date
❖ Oxygen:
Starting Date Weaning Date
Median Consumption (L /Day)
❖ Steroid:
Starting Date Weaning Date
Antivirals:
Starting Date Weaning Date
 Bronchodilators:
Starting Date Weaning Date
Name Name
❖ Mechanical Ventilation (Intubation):
Starting Date Weaning Date
 CPAP (Continuous Positive Airway Pressure):
Starting Date Weaning Date

Department of Health Research-Indian Council of Medical Research (DHR-ICMR)

INFORMED CONSENT FORM FOR COLLECTION OF SPECIMEN/S FOR INFLUENZA-SARSCOV-2 SURVEILLANCE THROUGH DHR-ICMR VRDL NETWORK

Study Title: Pan India Epidemiological, Virological and Genomic Surveillance for Human Influenza and COVID-19 through DHR-ICMR VRDL Network

Introduction and purpose of the study: Influenza and COVID-19 have a similar disease presentation, both cause upper and lower respiratory diseases which presents as a wide range of illness in children and adults. We are conducting a study to detect influenza and novel coronavirus (SARS CoV-2) among ILI and SARI cases and to identify the currently circulating strains of influenza virus in India. This surveillance study will help in early detection of newly emerging influenza virus strains and any unusual outbreak of influenza or influenza-like illness will be reported immediately. The activity will also be helpful to collect data on trend and proportion of existing and emerging variants of SRAS-CoV-2. Screening will also be beneficial to detect the nature of influenza virus against antiviral drug Tamiflu to establish its usefulness, especially in case of the newly emerged mutant influenza strains of pandemic potential. The information will be communicated to the World Health Organization (WHO) for understanding the global influenza situation and will have relevance on deciding vaccine development

Study procedure: A thin cotton swab will be inserted in the nose or throat of the patient for a few seconds and the mucus secretion collected. This is a safe procedure, when carried out by a trained investigator or technician. There will be no further follow up involved. In this on-going study, we will collect more than 500 samples per week from ILI and SARI patients.

strategies and develop anti-viral drugs.

Risk and benefits: There are no known or perceived complications associated with swab collection procedure. Participation in the study is a voluntary act. There will be no personal benefit for you and your treatment will not change due to this investigation, but the community at large would be benefited by your participation, by the knowledge gained through this research.

New findings: Any significant findings that will emerge during the course of the study will be provided to you by the investigator or study staff.

Confidentiality: Privacy of participant and confidentiality of the information obtained would be protected as permitted by law. Specimens will be identified by a code and all the records would be kept confidential and used for scientific purposes only. If you have any doubts or questions the investigator/s will give you required answers or clarifications.

Voluntary participation: Your/ your child's participation in this study would be voluntary and you have a right to refuse to participate in the study. Your child's medical treatment would not be affected even if you refuse to participate in the study.

Payment for participation: All the expenses for testing will be borne by the investigators and you will not have to make any payment for participation in the study. You will not be paid any amount for your participation in this study.

CONSENT

I confirm that I have read and understood the information given to me about the study (it has been read to me), and had opportunity to ask questions/doubts to the investigator/s. The questions have been answered to my satisfaction. I know that I have a right to refuse to participate in the study and this will not affect my right to receive treatment. I agree to allow my sample to be stored and used for future scientific research.

Subject's Name:	
Date:	
Signature/Thumb impression (in case illiterate patient) of patient/guardian	
Signature of witness	
Principal Investigator Dr. S. Dutta	

Principal Investigator

Name of Medical College /Institute

স্বাস্থ্য গবেষণা বিভাগ-ইন্ডিয়ান কাউন্সিল অফ মেডিক্যাল রিসার্চ (DHR-ICMR)

DHR-ICMR VRDL নেটওয়ার্কের মাধ্যমে ইনফ্লুয়েঞ্জা-সারসকোভ-2 সার্ভেল্যান্সের জন্য নমুনা সংগ্রহের জন্য অবহিত সম্মতি ফর্ম

অধ্যয়নের শিরোনাম: ডিএইচআর-আইসিএমআর ভিআরডিএল নেটওয়ার্কের মাধ্যমে প্যান ইন্ডিয়া এপিডেমিওলজিকাল, হিউম্যান ইনফ্লুয়েঞ্জা এবং কোভিড-১৯ এর জন্য ভাইরোলজিক্যাল এবং জিনোমিক নজরদারি

সূচনা এবং অধ্যয়নের উদ্দেশ্য: ইনফ্লুয়েঞ্জা এবং কোভিড-19 একই রকম রোগের উপস্থাপনা আছে, উভয়ই উপরের এবং নীচের শ্বাসযন্ত্রের রোগের কারণ হয়, যা শিশু এবং প্রাপ্তবয়স্কদের মধ্যে বিস্তৃত অসুস্থতা হিসাবে উপস্থাপন করে। আমরা ILI এবং SARI কেসগুলির মধ্যে ইনফ্লুয়েঞ্জা এবং নভেল করোনাভাইরাস (SARS CoV-2) সনাক্ত করার জন্য এবং ভারতে ইনফ্লুয়েঞ্জা ভাইরাসের বর্তমানে সঞ্চালিত স্ট্রেনগুলি সনাক্ত করার জন্য একটি গবেষণা পরিচালনা করছি৷ এই নজরদারি অধ্যয়ন নতুন উদীয়মান ইনফ্লুয়েঞ্জা ভাইরাস স্ট্রেনগুলির প্রাথমিক সনাক্তকরণে সাহায্য করবে এবং ইনফ্লুয়েঞ্জা বা ইনফ্লুয়েঞ্জার মতো অসুস্থতার অস্বাভাবিক প্রাদুর্ভাব অবিলম্বে রিপোর্ট করা হবে। SRAS-CoV-2 এর বিদ্যমান এবং উদীয়মান রূপগুলির প্রবণতা এবং অনুপাতের ডেটা সংগ্রহ করতেও এই কার্যকলাপটি সহায়ক হবে।

অ্যান্টিভাইরাল ড্রাগ Tamiflu এর বিরুদ্ধে ইনফ্লুয়েঞ্জা ভাইরাসের প্রকৃতি শনাক্ত করতেও স্ক্রীনিং উপকারী হবে, বিশেষ করে নতুনভাবে উদ্ভূত মিউট্যান্ট ইনফ্লুয়েঞ্জা স্ট্রেনের ক্ষেত্রে মহামারী সম্ভাব্যতা প্রতিষ্ঠা করতে। বৈশ্বিক ইনফ্লুয়েঞ্জা পরিস্থিতি বোঝার জন্য তথ্যগুলি বিশ্ব স্বাস্থ্য সংস্থা (WHO)-কে জানানো হবে এবং ভ্যাকসিন বিকাশের কৌশল নির্ধারণ এবং অ্যান্টি-ভাইরাল ওমুধ বিকাশের ক্ষেত্রে প্রাসঙ্গিক হবে।

অধ্যয়নের পদ্ধতি: রোগীর নাকে বা গলায় কয়েক সেকেন্ডের জন্য একটি পাতলা Swab Stick ঢোকানো হবে এবং শ্লেষ্মা নিঃসরণ সংগ্রহ করা হবে। এটি একটি নিরাপদ পদ্ধতি, যখন একজন প্রশিক্ষিত তদন্তকারী বা প্রযুক্তিবিদ দ্বারা পরিচালিত হয়। এই চলমান গবেষণায়, আমরা প্রতি সপ্তাহে ILI এবং SARI রোগীদের কাছ থেকে 500 টিরও বেশি নমুনা সংগ্রহ করব।

বুঁকি এবং সুবিধা: সোয়াব সংগ্রহ পদ্ধতির সাথে সম্পর্কিত কোন পরিচিত বা অনুভূত জটিলতা নেই। গবেষণায় অংশগ্রহণ একটি স্বেচ্ছাসেবী কাজ। আপনার জন্য কোনো ব্যক্তিগত সুবিধা হবে না এবং এই তদন্তের কারণে আপনার চিকিৎসার কোনো পরিবর্তন হবে না, তবে এই গবেষণার মাধ্যমে অর্জিত জ্ঞানের মাধ্যমে আপনার অংশগ্রহণের মাধ্যমে ব্যাপকভাবে সম্প্রদায় উপকৃত হবে।

নতুন অনুসন্ধান: অধ্যয়ন চলাকালীন যেকোন উল্লেখযোগ্য ফলাফল উদ্ভূত হবে তা আপনাকে তদন্তকারী বা অধ্যয়ন কর্মীরা প্রদান করবেন।

গোপনীয়তা: অংশগ্রহণকারীর গোপনীয়তা এবং প্রাপ্ত তথ্যের গোপনীয়তা আইন দ্বারা অনুমোদিত হিসাবে সুরক্ষিত হবে। নমুনা একটি কোড দ্বারা চিহ্নিত করা হবে এবং সমস্ত রেকর্ড গোপন রাখা হবে এবং শুধুমাত্র বৈজ্ঞানিক উদ্দেশ্যে ব্যবহার করা হবে। আপনার কোন সন্দেহ বা প্রশ্ন থাকলে তদন্তকারী আপনাকে প্রয়োজনীয় উত্তর বা স্পষ্টীকরণ দেবে।

স্বেচ্ছায় অংশগ্রহণ: এই অধ্যয়নে আপনার/আপনার সন্তানের অংশগ্রহণ স্বেচ্ছায় হবে এবং আপনার অধ্যয়নে অংশগ্রহণ করতে অস্বীকার করার অধিকার রয়েছে। আপনি গবেষণায় অংশগ্রহণ করতে অস্বীকার করলেও আপনার সন্তানের চিকিৎসা প্রভাবিত হবে না।

আংশগ্রহণের জন্য অর্থপ্রদান: পরীক্ষার জন্য সমস্ত খরচ তদন্তকারীরা বহন করবে এবং অধ্যয়নে অংশগ্রহণের জন্য আপনাকে কোনো অর্থপ্রদান করতে হবে না। এই গবেষণায় আপনার অংশগ্রহণের জন্য আপনাকে কোনো অর্থ প্রদান করা হবে না।

তদন্তকারীর যোগাযোগের বিশদ আপনার যদি অধ্যয়ন সম্পর্কিত কোন প্রশ্ন থাকে তবে আপনি তদন্তকারীদের সাথে যোগাযোগ করতে স্বাধীন এবং আপনাকে উপলব্ধ তথ্য সরবরাহ করা হবে। ট্রায়ালে অংশগ্রহণকারী হিসাবে অধিকার সম্পর্কে আপনার কোন সন্দেহ বা প্রশ্ন থাকলে অনুগ্রহ করে চেয়ারপারসন, এথিক্যাল কমিটি, এর সাথে যোগাযোগ করুন।

সম্মতি

আমি নিশ্চিত করি যে আমি অধ্যয়ন সম্পর্কে আমাকে দেওয়া তথ্য পড়েছি এবং বুঝেছি (এটি আমাকে পড়া হয়েছে), এবং তদন্তকারী/দের কাছে প্রশ্ন/সন্দেহ জিজ্ঞাসা করার সুযোগ পেয়েছি। প্রশ্নগুলো আমার সন্তুষ্টির জন্য উত্তর দেওয়া হয়েছে। আমি জানি যে অধ্যয়নে অংশগ্রহণ করতে অস্বীকার করার অধিকার আমার আছে এবং এটি আমার চিকিৎসা পাওয়ার অধিকারকে প্রভাবিত করবে না। আমি আমার নমুনা সংরক্ষণ এবং ভবিষ্যতে বৈজ্ঞানিক গবেষণার জন্য ব্যবহার করার অনুমতি দিতে সম্মত।

তারিখ:		
স্বাক্ষর/আঙুলের ছাপ (অশিক্ষিত রোগীর ক্ষেত্রে) রোগীর/অভিভাবকের		
সাক্ষী স্বাক্ষর		
তদন্তকারীর স্বাক্ষর		
প্রধান তদন্তকারী	 	
মেডিকেল কলেজ/ইনস্টিটিউটের নাম		

ICMR-NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES VIRUS RESEARCH AND DIAGNOSTIC LABORATORY

FORMAT NO. NICED/FM/90

PATIENT IDENTIFICATION (PID) SLIP

2			
	ation No.:	Requested:	
Site ID:	OPD/IPD Registration No.:	Investigation/s Requested:	Signature:

ICMR-NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES VIRUS RESEARCH AND DIAGNOSTIC LABORATORY

PATIENT IDENTIFICATION (PID) SLIP

FORMAT NO. NICED/FM/90

			-	
Site ID:	Name of Patient:	OPD/IPD Registration No.:	Investigation/s Requested:	Signature:

ICMR-NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES VIRUS RESEARCH AND DIAGNOSTIC LABORATORY

FORMAT NO. NICED/FM/90

PATIENT IDENTIFICATION (PID) SLIP

	95			
	ent:	OPD/IPD Registration No.:	Investigation/s Requested:	
Site ID:	Name of Patient:	OPD/IPD Reg	Investigation	Signature:

OPD/IPD Registration No.: _ Investigation/s Requested:

Signature:

Name of Patient:

Site ID:

ICMR-NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES VIRUS RESEARCH AND DIAGNOSTIC LABORATORY

FORMAT NO. NICED/FM/90

FORMAT NO. NICED/FM/90

PATIENT IDENTIFICATION (PID) SLIP

ICMR-NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES

VIRUS RESEARCH AND DIAGNOSTIC LABORATORY

PATIENT IDENTIFICATION (PID) SLIP

OPD/IPD Registration No.:_ Investigation/s Requested:

Signature:

Name of Patient:

Site ID:

ICMR-NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES VIRUS RESEARCH AND DIAGNOSTIC LABORATORY

FORMAT NO. NICED/FM/90

PATIENT IDENTIFICATION (PID) SLIP

Site ID:/
Name of Patient:
OPD/IPD Registration No.:
Investigation/s Requested:
Signature:

ICMR-NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES VIRUS RESEARCH AND DIAGNOSTIC LABORATORY

FORMAT NO. NICED/FM/90

PATIENT IDENTIFICATION (PID) SLIP

			d:	
Site ID:	Name of Patient:	OPD/IPD Registration No.:	Investigation/s Requested:	Signature:

ICMR-NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES VIRUS RESEARCH AND DIAGNOSTIC LABORATORY

FORMAT NO. NICED/FM/90

FORMAT NO. NICED/FM/90

PATIENT IDENTIFICATION (PID) SLIP

ICMR-NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES

VIRUS RESEARCH AND DIAGNOSTIC LABORATORY

PATIENT IDENTIFICATION (PID) SLIP

BETWEEN 11:00 AM TO 01:00 PM	DATE OF REPORT DELIVERY	BETWEEN 11:00 AM TO 01:00 PM	DATE OF REPORT DELIVERY	BETWEEN 11:00 AM TO 01:00 PM	DATE OF REPORT DELIVERY
BETWEEN 11:00 AM TO 01:00 PM	DATE OF REPORT DELIVERY	BETWEEN 11:00 AM TO 01:00 PM	DATE OF REPORT DELIVERY	BETWEEN 11:00 AM TO 01:00 PM	DATE OF REPORT DELIVERY
BETWEEN 11:00 AM TO 01:00 PM	DATE OF REPORT DELIVERY	BETWEEN 11:00 AM TO 01:00 PM	DATE OF REPORT DELIVERY	BETWEEN 11:00 AM TO 01:00 PM	DATE OF REPORT DELIVERY